Ask AI
ProCE Banner Activity

Real-world Lenacapavir in Heavily Treatment–Experienced People Living With HIV: Virologic Outcomes, Pill Burden, and Number of Total and Active Agents

Conference Coverage
Slideset

In a multicenter, real-world analysis of heavily treatment–experienced patients, virologic suppression was achieved and maintained by the majority of patients. ART regimens included more active agents, and daily pill burden decreased.

Released: October 29, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare